Patient ID/ gender | Age at diagnosis of rheumatologic disease (years) | Age at diagnosis of neoplasm (years) | Neoplasm | Anti-TNFα (dose/Duration) | Time from Rheumatologic diagnosis to neoplasm (years) | Time from start of anti-TNFα to neoplasm (years) | Concomitant and previous DMARD, cytotoxic agent and other Biologic (years) | Other concomitant and previous medications | Family history of malignancy |
---|---|---|---|---|---|---|---|---|---|
A/Female | Extended oligo JIA (1.6 years) | 17 | Ewing’s sarcoma | etanercept 25 mg biweekly × 2.6 years | 16.7 | 5.3 | methotrexate (7.2), leflunomide (0.2) | naprosyn, prednisone, folic acid | Unknown |
B/Female | Poly JIA (8.2 years) | 24 | renal clear cell carcinoma | etanercept 25 mg weekly × 4.8 years, infliximab 400 mg x one dose | 15.8 | 10.6 from etanercept, 4.4 from infliximab | rituximaba (2 doses), methotrexate (6.2), leflunomide (0.2), sulfasalazine (0.9), azathioprine (1.2), cyclosporine A (1.5) | naprosyn, prednisone, hydroxychloroquine, amitriptyline, oxycodone, depo-provera, folic acid | Unknown |
C/Female | Extended oligo JIA with anterior uveitis (2.0 years) | 14 | benign pilo-matricoma | infliximab 200–500 mg monthly × 0.25 years | 12.7 | 1.3 | cyclosporine A (3.2), azathioprine (4.3), methotrexate (6.0), leflunomide (2.8) | hydroxychloroquine, acetazolamide, alendronate, iron, calcium | Multiple family members with colon cancer |
D/Male | Idiopathic uveitis (10.8 years) | 16 | naso-pharyngeal cancer | infliximab 300–400 mg monthly × 3.3 years | 5.3 | 3.3 | methotrexate (4.7) | folic acid | Maternal grandfather with lung cancer; Maternal grandmother with cervical cancer |
E/Female | Systemic JIA (4.7years) | 16 | hepatic T-cell lymphoma | etanercept 10 mg biweekly × 0.1 years, infliximab (10 mg/kg) monthly × 1.7 years | 11.8 | 9.9 from etanercept, 8.6 from infliximab | anakinraa (1.9), cyclosporine A (0.9), methotrexate (3.6), tacrolimus (5.0), thalidomide (0.6), etoposide (6 doses) | prednisone | Unknown |
F/Male | Polyarteritis Nodosa (1.1 years) | 14/19 | lympho-proliferative disease (age 14); renal clear cell carcinoma (age 19) | infliximab (100 mg) monthly × 4.8 years | 14.1 to lympho-proliferative disease; 18.6 to renal clear cell carcinoma | 4.8 to lympho-proliferative disease; 9.3 to renal clear cell carcinoma | methotrexate (1.2), azathioprine (unknown), cyclophosphamide (1.5) | prednisone, enalopril, amlodipine, sulfamethoxazole, ranitidine, testosterone, protropin, nutropin, insulin, metformin, ferrous fumarate | Mother with breast cancer (deceased at age 31); Half-brother with suspected autoimmune lympho-proliferative disorder |
Median (IQR) | 3.4 (1.7–7.3) | 16.3 (15.3–17.9) | 5.0 (3.6–7.7) | methotrexate: 5.4 (3.9–6.1) |